Therapeutic Potential of Ralimetinib, a p38/MAPK14 Inhibitor, in Anaplastic Thyroid Cancer

Authors

Muthusamy Kunnimalaiyaan, The University of Texas MD Anderson Cancer Center
Ali Dadbin, The University of Texas MD Anderson Cancer Center
Ying Henderson, The University of Texas MD Anderson Cancer Center
Elena McBeath Fujiwara, The University of Texas MD Anderson Cancer Center
Clifford Stephan, The University of Texas MD Anderson Cancer Center
Roza Nurieva PhD, The University of Texas MD Anderson Cancer Center
Naifa L. Busaidy, The University of Texas MD Anderson Cancer Center
Jennifer R. Wang, The University of Texas MD Anderson Cancer Center
Stephen Lai, The University of Texas MD Anderson Cancer Center
Maria Cabanillas, The University of Texas MD Anderson Cancer Center
Marc E. Zafereo, The University of Texas MD Anderson Cancer Center
Ramona Dadu, The University of Texas MD Anderson Cancer Center
Marie-Claude Hofmann, The University of Texas MD Anderson Cancer Center

Files

Abstract

View full abstract

DOI

https://doi.org/10.52519/00062

Publication Date

2022

Department

Endocrine Neoplasia and Hormonal Disorders

Research Category

The Patient is the Focus

Recommended Citation

Kunnimalaiyaan, Muthusamy; Dadbin, Ali; Henderson, Ying; Fujiwara, Elena McBeath; Stephan, Clifford; Nurieva, Roza PhD; Busaidy, Naifa L.; Wang, Jennifer R.; Lai, Stephen; Cabanillas, Maria; Zafereo, Marc E.; Dadu, Ramona; and Hofmann, Marie-Claude, "Therapeutic Potential of Ralimetinib, a p38/MAPK14 Inhibitor, in Anaplastic Thyroid Cancer" (2022). Leading Edge of Cancer Research Symposium. 29.
doi:https://doi.org/10.52519/00062